ReviewFrontiers in oncology2026
From molecular crosstalk to precision therapy: targeting ferroptosis and cuproptosis in oral squamous cell carcinoma.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in ferroptosis mechanisms and therapeutic potential in head and neck squamous cell carcinoma.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral squamous cell carcinoma (OSCC) is one of the most common malignant tumors in the head and neck region, where conventional therapies have limited efficacy and patients have poor prognosis. As newly identified metal ion-dependent programmed cell death modalities, ferroptosis and cuproptosis play critical roles in tumor metabolism, immune microenvironment remodeling, and therapeutic resistance, representing emerging research foci in OSCC. This review examines the core molecular mechanisms of ferroptosis and cuproptosis and delineates their respective roles in OSCC initiation, progression, immune evasion, and therapeutic resistance. Furthermore, we explore the crosstalk between these two cell death modalities across oxidative stress, metabolic, and signaling networks. Synthesizing these findings, we outline emerging combination strategies that concurrently target ferroptosis and cuproptosis, and discuss current challenges and future directions for translating these concepts into precision therapies for OSCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.